Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment

Proglumide is an orally administered cholecystokinin receptor antagonist that was found to improve nonalcoholic steatohepatitis, reverse liver fibrosis, and decrease incidence of hepatocellular carcinoma (HCC) in animal models. The current investigation aimed to test the pharmacokinetics and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Christine C., Bansal, Sunil, Cao, Hong, Smith, Coleman I., He, Aiwu Ruth, Gay, Martha D., Li, Yaoxiang, Cheema, Amrita, Smith, Jill P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948956/
https://www.ncbi.nlm.nih.gov/pubmed/35336003
http://dx.doi.org/10.3390/pharmaceutics14030627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948956/
https://www.ncbi.nlm.nih.gov/pubmed/35336003
http://dx.doi.org/10.3390/pharmaceutics14030627

Ejemplares similares